Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15643545 | 0.87 | CYP19A1 (0.44) | ALDH1A1HTTSMN1; SMN2NPY1RNPY5R | |
| SCHEMBL14993097 | 0.83 | ADAMTS4 (0.45) | PRMT1ALDH1A1HTTSMN1; SMN2NPY1R | |
| SCHEMBL14992699 | 0.82 | NPY1R (0.44) | PRMT1ALDH1A1HTTSMN1; SMN2NPY1R | |
| SCHEMBL14333772 | 0.81 | SMN1; SMN2 (0.53) | PRMT1ALDH1A1HTTSMN1; SMN2NPY1R | |
| SCHEMBL15643340 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HTTSMN1; SMN2FFAR1NPY1R | |
| SCHEMBL4508326 | 0.79 | CYP19A1 (0.50) | PRMT1ALDH1A1HTTSMN1; SMN2NPY1R | |
| SCHEMBL14992892 | 0.79 | SMN1; SMN2 (0.47) | PRMT1ALDH1A1HTTSMN1; SMN2NPY1R | |
| SCHEMBL15643247 | 0.78 | CYP19A1 (0.48) | ALDH1A1HTTSMN1; SMN2ADAMTS4MMP13 | |
| SCHEMBL14334349 | 0.77 | KEAP1 (0.48) | PRMT1ALDH1A1HTTSMN1; SMN2NPY1R | |
| SCHEMBL15819472 | 0.76 | HTT (0.50) | ALDH1A1HTTSMN1; SMN2ADAMTS4MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315857-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. DUPONT DE NEMOURS AND COMPANY | 2014-10-23 | — | — | US | disclosed |
| EP-2785694-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. Du Pont de Nemours and Company (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013081783-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315857-A1 | N- (4 -QUINOLINYLMETHYL) SULFONAMIDE DERIVATIVES AND THEIR USE AS ANTHELMINTICS | NQO2, SQOR, QSOX1 | PRMT1 334/4885ALDH1A1 506/4885HTT 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.